title: Quality of Life After Off-Label Thrombolysis for Ischemic Stroke in Elderly Patients.
abstract: BACKGROUND
  The use of intravenous thrombolysis with alteplase for ischemic stroke in Europe is restricted to subjects aged <80 years. Recent studies have reported the efficacy and safety of alteplase in older patients. However, data concerning the quality of life (QOL) of these elderly subjects are sparse.
  
  
  OBJECTIVE
  The aim of this study was to compare the QOL of patients aged ≥80 years with that of patients aged <80 years at 3 months after thrombolysis.
  
  
  METHODS
  This was a prospective study comprising French-speaking patients aged >18 years treated using thrombolytic therapy for ischemic stroke at the Hospital of Tours (Tours, France) between June 2012 and January 2013. QOL was assessed using the Stroke Impact Scale (SIS). The presence of mood disorders or cognitive impairments was also assessed.
  
  
  RESULTS
  QOL was evaluated for 62 subjects among the 83 enrolled patients who received thrombolytic treatment; 21 patients were aged >80 years. Concerning scores on the SIS, using a multivariate analysis, only the memory and thinking score was significantly and negatively associated with the elderly population [odds ratio (OR) 0.036, 95% confidence interval (CI) 0.004-0.339; p = 0.004]. No significant difference was observed among all the other QOL scores. Neurological recovery and functional status did not differ between the two groups.
  
  
  CONCLUSIONS
  QOL after intravenous thrombolysis in the elderly population was comparable to that of younger subjects. Despite its small sample size, this study showed promising results in favor of intravenous thrombolysis in the elderly population and highlighted the importance of systematic screening for post-stroke cognitive impairment, particularly in this population.
authors.affiliation: Department of Neurology, Hôpital Bretonneau, University Hospital of Tours, 2 boulevard Tonnellé, 37000, Tours, France. capucine.diarddetoeuf@gmail.com.
authors.forename: Capucine
authors.initials: C
authors.lastname: Diard-Detoeuf
authors.affiliation: Department of Neurology, Hôpital Bretonneau, University Hospital of Tours, 2 boulevard Tonnellé, 37000, Tours, France.
authors.forename: Séverine
authors.initials: S
authors.lastname: Debiais
authors.affiliation: Department of Neurology, Hôpital Bretonneau, University Hospital of Tours, 2 boulevard Tonnellé, 37000, Tours, France.
authors.forename: Mélanie
authors.initials: M
authors.lastname: Imbert
authors.affiliation: Department of Neurology, Hôpital Bretonneau, University Hospital of Tours, 2 boulevard Tonnellé, 37000, Tours, France.
authors.forename: Alexandra
authors.initials: A
authors.lastname: Musikas
authors.affiliation: Department of Neurology, Hôpital Bretonneau, University Hospital of Tours, 2 boulevard Tonnellé, 37000, Tours, France.
authors.forename: Marie
authors.initials: M
authors.lastname: Gaudron
authors.affiliation: Laboratory of Epidemiology and Public Health, Faculty of Medicine, François Rabelais University, Tours, France.
authors.forename: Emeline
authors.initials: E
authors.lastname: Laurent
authors.affiliation: Department of Neurology, Hôpital Bretonneau, University Hospital of Tours, 2 boulevard Tonnellé, 37000, Tours, France.
authors.forename: Bertrand
authors.initials: B
authors.lastname: De Toffol
authors.affiliation: Department of Geriatrics and Memory Center, University Hospital of Tours, Tours, France.|UMR INSERM U930, François Rabelais University, Tours, France.
authors.forename: Caroline
authors.initials: C
authors.lastname: Hommet
authors.affiliation: Department of Geriatrics and Memory Center, University Hospital of Tours, Tours, France.|UMR INSERM U930, François Rabelais University, Tours, France.
authors.forename: Karl
authors.initials: K
authors.lastname: Mondon
mesh_terms: D061605:Administration, Intravenous; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D002545:Brain Ischemia / Q000150:complications / Q000188:drug therapy*; D003072:Cognition Disorders / Q000150:complications; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D019964:Mood Disorders / Q000150:complications; D056687:Off-Label Use; D011446:Prospective Studies; D011788:Quality of Life; D020521:Stroke / Q000150:complications / Q000188:drug therapy*; D015912:Thrombolytic Therapy / Q000009:adverse effects*; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator